Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Same Day Versus Next Day Discharge: Ambulatory Closure Device Percutaneous Intervention (ABCD-PCI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01230606
Recruitment Status : Completed
First Posted : October 29, 2010
Last Update Posted : July 28, 2011
Sponsor:
Collaborator:
Abbott Medical Devices
Information provided by:
Icahn School of Medicine at Mount Sinai

Brief Summary:
This is a multi-center trial that will evaluate the safety, feasibility, and cost effectiveness of discharging patients, who have had successful percutaneous coronary intervention (PCI) and deployment of the AngiomaxTM closure device, 6 hours after against 24 hours after the procedure. Patients will be randomized in a 3 (test): 1 (control) fashion and will have a study population of 600 patients over 6 investigational sites all within the United States. Patients <65 years old will be chosen in order to stay within the low risk group and will be followed up after 24 hours, 7 days, and 30 days via phone or office visit. The primary endpoint will be a composite of major adverse cardiac and cerebral events, and the incidence of major bleeding or vascular complications. Data acquired from the study, such as blinded financial information and patient satisfaction surveys, will be used in order to evaluate cost analysis and safety of the procedure.

Condition or disease Intervention/treatment
Cardiovascular Disease Other: discharge vs. overnight stay

Detailed Description:
Closure devices are a relatively new method for sealing the femoral arterial puncture following procedures including percutaneous intervention (PCI). Because the risk of severe complications (e.g., bleeding, myocardial infarction, stroke, and mortality) associated with PCI when closure devices are very low, many patients undergoing PCI may be considered eligible for a same day hospital discharge. As the practice of ambulatory PCI is becoming more common, it is important to evaluate the readiness of patients under-going PCI for same-day discharge and anxiety and coping abilities of patients post-discharge. Our hypothesis is that same day discharge of patients who have undergone a PCI procedure with closure using a vascular closure device is safe, patients will be comfortable with a same day discharge and this process will be more cost efficient than the current standard of staying in the hospital overnight. The current pilot study is a multi-center, randomized parallel arm, controlled trial of low-risk patients undergoing an elective PCI procedure. Overall, 600 patients will be enrolled. After providing informed consent, participants will be randomized to leave the hospital on the same day as the PCI procedure or stay overnight in a 1:1 ratio. Data collection includes a self-administered questionnaire at hospital discharge, telephone interviews at 7-days and 30-days post-hospital discharge, and chart abstraction. The primary outcome for this study is differences across randomization arm in patient satisfaction scores on the validated 10-item Post-discharge coping difficulty scale assessed 7 days post-discharge. Secondary outcomes will include differences across randomization group for symptoms of anxiety, readiness for hospital discharge, patient satisfaction with the timing of their discharge, post-procedure pain and soreness, and cost-savings. While a data safety monitoring board will track all adverse events (i.e., myocardial infarction, hematoma, hospitalizations, and mortality), we anticipate too few events to occur to make meaningful inferences beyond that PCI is safe regardless of the timing of hospital discharge. The data from this pilot study will determine the comfort patients experience after undergoing PCI with an ambulatory (i.e, same-day) hospital discharge. Furthermore, this pilot study will provide the foundation for a large scale non-inferiority study of same-day discharge on outcomes including myocardial infarction, bleeding, and mortality. Such data will indicate the overall feasibility of early ambulatory PCI and has the potential to radically alter health care delivery following PCI.

Layout table for study information
Study Type : Observational
Actual Enrollment : 303 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Ambulatory Closure Device Percutaneous Intervention: a Multi-Center Randomized Trial Evaluating Patient Satisfaction, Safety, and Cost Effectiveness of Ambulatory PCI in the Current Era
Study Start Date : January 2008
Actual Primary Completion Date : June 2010
Actual Study Completion Date : June 2010

Group/Cohort Intervention/treatment
overnight
Subjects that stay overnight at the hospital.
Other: discharge vs. overnight stay
At six hours post-PCI,patients will be randomized to be discharged immediately or to stay overnight in the hospital for observation and discharged the following day. Randomization will occur in a 1:1 ratio. Additionally, randomization will be performed stratified by study site.

Next Day Discharge
Subjects that are discharged on the same day of the procedure.
Other: discharge vs. overnight stay
At six hours post-PCI,patients will be randomized to be discharged immediately or to stay overnight in the hospital for observation and discharged the following day. Randomization will occur in a 1:1 ratio. Additionally, randomization will be performed stratified by study site.




Primary Outcome Measures :
  1. Post-hospitalization patient satisfaction [ Time Frame: 30 days after enrollment ]
    The primary endpoint is the difference in post-hospitalization patient satisfaction during the initial seven days following PCI. Post-hospitalization patient satisfaction will be assessed using the 10-item Post-Discharge Coping Difficulty scale.


Secondary Outcome Measures :
  1. Patient satisfaction with timing of discharge [ Time Frame: 30 days after enrollment ]
    Secondary outcomes will include post-hospital anxiety, readiness for hospital discharge, patient satisfaction with the timing of their discharge, post-procedure pain and soreness, resource utilization and cost-savings.

  2. Patient Satisfaction Outcome Assessment [ Time Frame: 30 days After Enrollment ]
    These outcomes will be assessed using standardized questionnaires and validated techniques. The composite of major adverse cardiac events (MACE) and cerebral events and the incidence of major bleeding or vascular complications will be monitored for all patients through the 30 day follow-up period.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
The target population for this study will include patients undergoing an elective PCI. Overall, 600 patient will be recurited from two sites in the United Sates. As this is a feasiblity study, enrollment will be restricted to low-risk patients. For this reason, the study will be limited to patients under 75 years of age. All patients must meet all of the inclusion criteria and have none of the exclusion criteria to be enrolled into the study.
Criteria

Inclusion Criteria:

. <75 years of age at the time of procedure.

2. Patient has a type A or B lesion(s)

3. Femoral access site is amenable to closure with a vascular closure device.

4. Over 2 hours since the completion of the PCI procedure (at least 2 hours must elapse from completion of the PCI before subjects become eligible).

Exclusion Criteria:

  1. Patient has a life expectancy less than 12 months.
  2. Patient has recent evidence of an acute coronary syndrome (MI)
  3. Femoral access is difficult or site is not amenable to closure device
  4. Anticoagulants other than unfractionated heparin or bivalirudin were used during the procedure (i.e. enoxaparin).
  5. Patient has sub optimal angiographic outcome or clinical complication(s) during PCI
  6. The PCI occurred in something other than a native coronary artery
  7. Angiographic evidence of thrombus
  8. Patient has more than 3 stents implanted during this PCI
  9. Patient has an INR >2, Platelet count <100,000 or Hematocrit <25
  10. Occlusion of major side branch during PCI of >1.5mm
  11. Patient has ejection fraction ≤30%
  12. Known allergy to PCI procedural medications
  13. Patient reports living further than 30 minutes from a hospital by ambulance.
  14. Patient provides informed consent and agrees to the follow-up schedule.
  15. Evidence of vascular complication(s) (e.g. dissection, hematoma, bleeding) peri-procedure
  16. Patient is pregnant
  17. Evidence of infection (e.g. fever, pus, swelling) peri-procedure
  18. Patients with chronic renal insufficiency (e.g. serum creatinine ≥1.5 mg/dL)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01230606


Locations
Layout table for location information
United States, New York
Mount Sinai School of Medicine
New York, New York, United States, 10029
United States, Texas
Baylor University Medical Center
Dallas, Texas, United States, 75226
Sponsors and Collaborators
Icahn School of Medicine at Mount Sinai
Abbott Medical Devices
Investigators
Layout table for investigator information
Principal Investigator: Michael C Kim, MD Icahn School of Medicine at Mount Sinai
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Dr. Michael C. Kim, Mount Sinai School of Medicine
ClinicalTrials.gov Identifier: NCT01230606    
Other Study ID Numbers: GCO 07-1324
First Posted: October 29, 2010    Key Record Dates
Last Update Posted: July 28, 2011
Last Verified: July 2011
Keywords provided by Icahn School of Medicine at Mount Sinai:
Percutaneous Intervention
Percutaneous Coronary Intervention
Catheterization
Coronary Catheterization
Same day Discharge
Next Day Discharge
Patient Satisfaction
Multi-Center
Randomized
Low-risk PCI
BlindedClosure device
Vascular closure device
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiovascular Diseases